Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C76H104N18O19S2 |
Molecular Weight | 1637.878 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@]([H])(NC(=O)[C@H](CC6=CC=CC=C6)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
InChI
InChIKey=NHXLMOGPVYXJNR-ATOGVRKGSA-N
InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t41-,42+,43+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-,63-/m0/s1
Molecular Formula | C76H104N18O19S2 |
Molecular Weight | 1637.878 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 2 |
Optical Activity | UNSPECIFIED |
Somatostatin (also known as growth hormone-inhibiting hormone) is a naturally-occurring peptide hormone that regulates the endocrine system. Somatostatin is produced in gastrointestinal (GI) tract, pancreas, hypothalamus, and central nervous system (CNS) and some other organs. Somatostatin is initially secreted as a 116 amino acid precursor, preprosomatostatin, which undergoes endoproteolytic cleavage to prosomastatin. Prosomastatin is further process into two active forms, shorter isoform somatostatin-14 works primarily in the brain, while the longer somatostatin-28 (SST-28) form operates in the GI tract. Somatostatin produces predominantly neuroendocrine inhibitory effects across multiple systems. It is known to inhibit GI, endocrine, exocrine, pancreatic, and pituitary secretions, as well as modify neurotransmission and memory formation in the CNS. Somatostatin binds to six different receptors in various systems and cells throughout the body to produce its regulatory effect. These receptors are specific to somatostatin and classify as G-protein coupled receptors (GPCR). Somatostatin half-life is between 1 to 3 minutes. Due to its short half-life, somatostatin has been formulated exogenously in much more stable forms with a longer half-life; this allows for its primary clinical use, which is the treatment of neuroendocrine tumors.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 19:47:46 GMT 2023
by
admin
on
Sat Dec 16 19:47:46 GMT 2023
|
Record UNII |
6E20216Q0L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
21587
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
||
|
FDA ORPHAN DRUG |
86094
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
||
|
LOINC |
2960-3
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
||
|
LOINC |
49792-5
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
||
|
WHO-VATC |
QH01CB01
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
||
|
WHO-ATC |
H01CB01
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
||
|
LOINC |
2961-1
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6E20216Q0L
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
51110-01-1
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
100000092022
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
DB09099
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
2997
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL1823872
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
38916-34-6
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
SUB12320MIG
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
m10111
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
16129706
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
4311
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
64628
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
254-186-5
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
DTXSID8046793
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
9939
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | RxNorm | ||
|
256-969-7
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
ALTERNATIVE | |||
|
D013004
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY | |||
|
C836
Created by
admin on Sat Dec 16 19:47:48 GMT 2023 , Edited by admin on Sat Dec 16 19:47:48 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
AGONIST -> TARGET |
|
||
|
INDUCER -> TARGET |
ACTIVATES RELEASE OF SOMATOSTAIN
|
||
|
INGREDIENT -> STARTING MATERIAL |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|